What important information does Seleniso’s instructions contain?

Selinexor is a new type of selective nuclear export inhibitor (SINE drug). It mainly inhibits the protein export channel mediated by XPO1 (nuclear export protein 1), enhances the retention of intracellular anti-tumor proteins, and thereby promotes the apoptosis of malignant cells. The drug is approved by the FDA for the treatment of multiple myeloma (Multiple Myeloma) and certain types of diffuse large B-cell lymphoma (DLBCL). It is especially suitable for patients who have relapsed or are refractory after multiple lines of treatment. The following is an interpretation of Selinexor’s detailed medication instructions and usage guidelines:

1. Basic drug information

Common name:Selinexor

Product name:Xpovio

Dosage form: oral tablet

Common specifications:20mg/tablet

Storage conditions: normal temperature (20-25°C), avoid high temperature, humidity and direct sunlight, no refrigeration required

Packaging form: provided in bottles according to the course of treatment, sealed and stored to avoid accidental contact by children

2. Indications and applicable groups

Multiple myeloma: Indicated for adult patients who have relapsed or been refractory to treatment with at least one proteasome inhibitor and one immunomodulator

Diffuse large lymphomaB-cell lymphoma (DLBCL): used to treat adult patients with relapsed or refractory DLBCL after receiving more than two systemic therapies, including non-germinal center and transformed subtypes

Combined therapy: often used in combination with dexamethasone (Dexamethasone) to enhance anti-tumor activity.

3. Usage and dosage guidance

Frequency of medication: The standard regimen is usually oral twice a week (such as Mondays and Thursdays), which will be adjusted based on the indications and individual tolerance.

Dosage recommendation: The initial recommended dose is generally 80mg (4 tablets) each time, used in combination with dexamethasone; some patients can be adjusted to 60mg or 40mg according to weight and toxicity.

Medication time: Can be taken with meals to reduce gastric irritation. Swallow the tablet whole with water. Do not chew or break it.

4. Precautions and adverse reactions

Common side effects: fatigue, decreased appetite, hyponatremia, nausea, vomiting, diarrhea, weight loss, thrombocytopenia, etc.

Monitoring indicators: It is recommended to regularly monitor electrolyte levels, blood routine, liver and kidney function indicators to prevent severe adverse reactions

Drug interactions: Avoid coadministration with strongCYP3A4 inducers or inhibitors, and adjust the dose if necessary

Special groups: For the elderly and patients with hepatic or renal insufficiency, individual dosage adjustment is required. Please consult a hematology and oncology specialist before use.

5. Pretreatment and supportive care

Pretreatment recommendations: To prevent nausea, vomiting and other gastrointestinal side effects, oral antiemetics (such as ondansetron) can be taken 30 minutes before medication

Supportive treatment measures: Moderate fluid rehydration, electrolyte balance adjustment, nutritional intervention and psychological support are also important components to ensure curative effect.

Medication compliance: Patients need to be reminded to strictly follow the doctor’s instructions for medication and are not allowed to stop medication or change the dosage without authorization.

With the development of precision medicine, selinesol provides a new treatment path for patients with multiple myeloma and refractory lymphoma, and its unique mechanism brings hope for disease control after drug resistance. However, its toxic and side effects cannot be ignored, and it needs to be used in a standardized manner under the guidance of a professional doctor. Individualized management is very important.

Reference materials:https://www.selincro.com/